Start the conversation
Canada was in the headlines all weekend – but, as far as I'm concerned, the most earth-shattering news went almost totally unreported.
This is the culmination of more than seven months of research and parliamentary debate among five separate committees. After repeated, firm, public promises among legislators – including the Prime Minister, Justin Trudeau – an incalculable amount of political capital was on the line.
And sure enough, on Thursday, right around the time world leaders started arriving in Quebec for what would be an extremely contentious G7 summit, the Senate of Canada voted in a late-night session to legalize the recreational use of marijuana across the country.
That means Canada is right at the doorstep of being the first G7 nation to open the door to legal, regulated weed.
That's right: It's not a done deal… yet. Despite rhetoric calling for legal weed sales to begin by July 1, 2018, there are still two dominoes that have to fall for legalization to come into force.
As you'll see in a second, full legalization is still a virtual certainty, but now we have some extra time – just a little – to take a look at our weed holdings with exposure to Canada…
… and make sure we're loaded up on the right stocks before this thing explodes into the markets.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.